Patents by Inventor Pei-Chang Wu

Pei-Chang Wu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for treating myopia with an nsaid and an anti-muscarinic agent
    Patent number: 10888556
    Abstract: Pharmaceutical compositions containing a combination of anti-chondrogenesis agents are disclosed. Methods of reducing scleral chondrogensis, reducing one or more ocular chondrogenic proteins, reducing inflammation induced chondrogensis and treating myopia by administering an effective amount of one or more anti-chondrogensis agents are also provided. The pharmaceutical compositions are useful for treating myopia.
    Type: Grant
    Filed: December 3, 2019
    Date of Patent: January 12, 2021
    Assignees: Kaohsiung Chang Gung Memorial Hospital
    Inventors: Pei-Chang Wu, Chia-Ling Tsai, Chueh-Tan Chen
  • PHARMACEUTICAL COMPOSITION AND USES THEREOF
    Publication number: 20200113890
    Abstract: Pharmaceutical compositions containing a combination of anti-chondrogenesis agents are disclosed. Methods of reducing scleral chondrogensis, reducing one or more ocular chondrogenic proteins, reducing inflammation induced chondrogensis and treating myopia by administering an effective amount of one or more anti-chondrogensis agents are also provided. The pharmaceutical compositions are useful for treating myopia.
    Type: Application
    Filed: December 3, 2019
    Publication date: April 16, 2020
    Inventors: Pei-Chang Wu, Chia-Ling Tsai, Chueh-Tan Chen
  • Pharmaceutical composition and uses thereof
    Patent number: 10548887
    Abstract: Pharmaceutical compositions containing a combination of anti-chondrogenesis agents are disclosed. Methods of reducing scleral chondrogenesis, reducing one or more ocular chondrogenic proteins, reducing inflammation induced chondrogenesis and treating myopia by administering an effective amount of one or more anti-chondrogenesis agents are also provided. The pharmaceutical compositions are useful for treating myopia.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: February 4, 2020
    Assignees: Kaohsiung Chang Gung Memorial Hospital, Philip WU
    Inventors: Pei-Chang Wu, Chia-Ling Tsai, Chueh-Tan Chen
  • PHARMACEUTICAL COMPOSITION AND USES THEREOF
    Publication number: 20180311227
    Abstract: Pharmaceutical compositions containing a combination of anti-chondrogenesis agents are disclosed. Methods of reducing scleral chondrogenesis, reducing one or more ocular chondrogenic proteins, reducing inflammation induced chondrogenesis and treating myopia by administering an effective amount of one or more anti-chondrogenesis agents are also provided. The pharmaceutical compositions are useful for treating myopia.
    Type: Application
    Filed: April 20, 2018
    Publication date: November 1, 2018
    Inventors: Pei-Chang Wu, Chia-Ling Tsai, Chueh-Tan Chen
  • PHARMACEUTICAL COMPOSITION AND USES THEREOF
    Publication number: 20160067238
    Abstract: Pharmaceutical compositions containing a combination of anti-chondrogenesis agents are disclosed. Methods of reducing scleral chondrogensis, reducing one or more ocular chondrogenic proteins, reducing inflammation induced chondrogensis and treating myopia by administering an effective amount of one or more anti-chondrogensis agents are also provided. The pharmaceutical compositions are useful for treating myopia.
    Type: Application
    Filed: May 5, 2014
    Publication date: March 10, 2016
    Inventors: Pei-Chang Wu, Chia-Ling Tsai, Chueh-Tan Chen
  • Low-concentration atropine solution for preventing myopia progression and preparing method thereof
    Publication number: 20070254914
    Abstract: A low-concentration atropine solution for preventing myopia progression contains an atropine concentration less than 0.1% (w/w). Preferably, the atropine concentration is 0.05% (w/w) in optimal situation. The low-concentration atropine solution in treatment causes less photophobia and systemic side-effects to patients and has excellent compliance to reduce damages from ultraviolet and hazard blue light and to avoid visual morbidities such as cataract and retinal macula lutea deterioration.
    Type: Application
    Filed: May 1, 2006
    Publication date: November 1, 2007
    Applicant: Non-Profit Organization Chang Gung Memorial Hospital
    Inventors: Pei-Chang Wu, Hsi-Kung Kuo, Po-Chiung Fang, Jong-Jer Lee, Chih-Hsin Chen